scholarly journals Serum biomarkers in patients with stable and acute exacerbation of chronic obstructive pulmonary disease: A comparative study

2019 ◽  
Vol 38 (4) ◽  
pp. 503-511 ◽  
Author(s):  
Füsun Şahin ◽  
Ayşe Filiz Koşar ◽  
Ayşe Feyza Aslan ◽  
Burcu Yiğitbaş ◽  
Berat Uslu
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Acute Exacerbation ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Distribution Width ◽  
Lymphocyte Ratio ◽  
Group 3 ◽  
Group 2 ◽  
Group 1

Summary Background Mean platelet volume (MPV), neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have all been investigated as novel inflammatory markers of cardiac and oncological diseases, while there is only a limited number of studies investigating these markers in chronic obstructive pulmonary disease (COPD). In the present study we examine NLR, PLR; and other markers, such as eosinophil, MPV, plateletcrit (PCT), platelet distribution width (PDW), red cell distribution width (RDW), and C-reactive protein (CRP) in patients with stable and acute exacerbation of COPD. Methods Stable COPD (Group 1, n=140), COPD with acute exacerbation (Group 2, n=110), and healthy controls (Group 3, n=50) were included in the study. Leukocyte, CRP, hemoglobin (HB), RDW, platelet, MPV, PCT, PDW, neutrophil, lymphocyte, eosinophil, NLR, and PLR were analyzed in all groups. Results HB, leukocyte, platelet, neutrophil, eosinophil, MPV, PCT, CRP, NLR, and PLR were significantly higher, while the lymphocyte was lower in Group 1 than in Group 3. Leukocyte, neutrophil, RDW, CRP, NLR, and PLR were significantly higher, while lymphocyte was lower in Group 2 than in Group 3. Leukocyte, neutrophil, RDW, CRP, NLR, and PLR were significantly higher, while HB, platelet, MPV, PCT, and lymphocyte were significantly lower in Group 2 than in Group 1. NLR and PLR increased significantly in patients with bronchiectasis when compared to those without in Group 1. Conclusions Our study results suggest that NLR, PLR and RDW can be used as simple and cost-effective markers for the evaluation of severity of exacerbation and for predicting hospitalization and further exacerbations in patients with COPD.

The role of presepsin in the diagnosis of chronic obstructive pulmonary disease acute exacerbation with pneumonia

2020 ◽  
Vol 14 (1) ◽  
pp. 31-41
Author(s):  
Ali Halıcı ◽  
İzzettin Hür ◽  
Kerim Abatay ◽  
Esra Çetin ◽  
Filiz Halıcı ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Acute Exacerbation ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Acute Exacerbation Of Copd ◽  
Group 3 ◽  
Group 2 ◽  
Exacerbation Of Copd ◽  
Group 1

Aim: In this study, we aimed to investigate the role of presepsin in detecting concomitant pneumonia in patients presenting with acute exacerbation of chronic obstructive pulmonary disease (COPD) in the emergency department. Patients & methods: Three groups were formed in the study. Group 1: patients diagnosed with acute exacerbation of COPD; group 2: patients with acute exacerbation of COPD + pneumonia; group 3: healthy individuals. Results: Presepsin levels of the patients in group 2 were significantly higher than those of group 1 and group 3 (p < 0.05). There was a statistically significant difference in erythrocyte sedimentation rate, CRP, procalcitonin and presepsin values between two patient groups (p < 0.05). Conclusion: Presepsin can be used to diagnose pneumonia in patients with acute exacerbation of COPD admitted to the emergency department.

scholarly journals NEUTROPHIL TO LYMPHOCYTE RATIO AS A MARKER OF ACUTE EXACERBATION AND DISEASE SEVERITY IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE

2020 ◽  
pp. 46-47
Author(s):  
A. Yogalakshmee ◽  
P. Manimekalai ◽  
Priyanka Priyanka
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Acute Exacerbation ◽  
Disease Severity ◽  
Chronic Obstructive ◽  
Exclusion Criteria ◽  
Obstructive Pulmonary Disease ◽  
Lymphocyte Ratio ◽  
Medical College ◽  
One Year

The study is conducted on patients attending Sree Balaji Medical College and Hospital, Chennai during the study period . A sum total of 100 patients with Chronic Obstructive Pulmonary Disease attending Sree Balaji Medical College and Hospital was included in the study, based on the inclusion and exclusion criteria. The study is done after getting informed signed consent from the patients participated in the same. Duration of study was one year.

scholarly journals Papel da relação neutrófilo-linfócito no valor prognóstico para exacerbação e mortalidade entre indivíduos com Doença Pulmonar Obstrutiva Crônica: revisão integrativa da literatura

2021 ◽  
Vol 10 (12) ◽  
pp. e86101220080
Author(s):  
Barbara Rocha Alves Araújo ◽  
Clara Alvina Davi Coelho ◽  
Júlia Oliveira Santos ◽  
Marcella Luciano de Oliveira ◽  
Rita de Cássia Medeiros Queiroz ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Acute Exacerbation ◽  
Neutrophil To Lymphocyte Ratio ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Lymphocyte Ratio ◽  
Para Determinar

A DPOC é uma doença caracterizada por restrição do fluxo aéreo, inflamação sistêmica e a períodos de exacerbação aguda. Recentemente, demonstrou-se que a relação neutrófilo-linfócito (RNL) é preditor sensível de exacerbação aguda e do prognóstico do paciente com DPOC. Objetivou-se discutir a conformidade entre a RNL na exacerbação da DPOC, apresentando informações que correlacionam a alteração leucocitária com o agravamento dos sintomas e do desfecho do paciente com DPOC. Assim, foi realizada revisão Integrativa da literatura na base de dados PubMed das produções dos últimos 10 anos. Os descritores utilizados foram: “Neutrophil to Lymphocyte Ratio”, “Chronic Obstructive Pulmonary Disease” e “Acute Exacerbation”, os quais foram conjugados para delimitação da busca. Foram selecionados 10 artigos ao final das buscas, sendo os anos de 2015, 2018 e 2020 os mais prevalentes com 20% das publicações cada um. Os estudos tiveram origem na Turquia, responsável por 40% deles, 30% das publicações foram realizadas na China, e Irã, Israel e Japão, cada país com 10%. Encontrou-se níveis mais altos de RNL em pacientes que tiveram morte intra-hospitalar (≥ 4) e admissão hospitalar (≥ 2,7). Todavia, alguns estudos demonstraram que a RNL não é útil para determinar o fenótipo eosinofílico da DPOC exacerbada, e que marcadores inflamatórios se elevam distintamente de acordo com o endotipo de exacerbação. Portanto, a RNL é parâmetro simples e custo efetivo para predição, acompanhamento e prognóstico da exacerbação aguda de DPOC, inclusive nos pacientes estáveis, evidenciando associação positiva entre exacerbação aguda e relações celulares nos pacientes portadores de DPOC.

scholarly journals Role of the Emphysema Index Combined with the Chronic Obstructive Pulmonary Disease Assessment Test Score in the Evaluation of Chronic Obstructive Pulmonary Disease

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Qi Ding ◽  
Xia Wei ◽  
Jie Li ◽  
Yan-Zhong Gao ◽  
Shu-Di Xu ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Chronic Bronchitis ◽  
Pulmonary Disease ◽  
Quantitative Computed Tomography ◽  
Disease Assessment ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Group 4 ◽  
Group 3 ◽  
Group 2

Background. This study aimed to evaluate the efficacy of the emphysema index (EI) in distinguishing chronic bronchitis (CB) from chronic obstructive pulmonary disease (COPD) and its role, combined with the COPD Assessment Test (CAT) score, in the evaluation of COPD. Methods. A total of 92 patients with CB and 277 patients with COPD were enrolled in this study. Receiver operating characteristic (ROC) curves were analyzed to evaluate whether the EI can preliminarily distinguish chronic bronchitis from COPD. Considering the heterogeneity of COPD, there might be missed diagnosis of some patients with bronchitis type when differentiating COPD patients only by EI. Therefore, patients with COPD were classified according to the CAT score and EI into four groups: Group 1 (EI < 16%, CAT < 10), Group 2 (EI < 16%, CAT ≥ 10), Group 3 (EI ≥ 16%, CAT < 10), and Group 4 (EI ≥ 16%, CAT ≥ 10). The records of pulmonary function and quantitative computed tomography findings were retrospectively analyzed. Results. ROC curve analysis showed that EI = 16.2% was the cutoff value for distinguishing COPD from CB. Groups 1 and 2 exhibited significantly higher maximal voluntary ventilation (MVV) percent predicted (pred), forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC), maximal midexpiratory flow of 25–75% pred, carbon monoxide-diffusing capacity (DLCO)/alveolar ventilation (VA), FEV1 % pred p ≤ 0.013 , and maximal expiratory flow 50% pred (all p < 0.05 ) than Group 4. FEV1/FVC and DLCO/VA were significantly lower in Group 3 than in Group 2 ( p = 0.002 and p < 0.001 , respectively). The residual volume/total lung capacity was higher in Group 3 than in Groups 1 and 2 p < 0.05 . Conclusions. The combination of EI and CAT was effective in the evaluation of COPD.

scholarly journals How to improve the effectiveness of combination therapy of arterial hypertension in patients with concomitant chronic obstructive pulmonary disease?

2020 ◽  
Vol 4 (7) ◽  
pp. 418-424
Author(s):  
N.Yu. Grigorieva ◽  
◽  
M.O. Samolyuk ◽  
T.V. Sheshina ◽  
N.B. Koroleva ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Lipid Peroxidation ◽  
Arterial Hypertension ◽  
Pulmonary Disease ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Number Of Patients ◽  
Group 2 ◽  
Azilsartan Medoxomil ◽  
Group 1

Aim: to conduct a comparative assessment of the hypotensive effect, as well as the effect on endothelial function, oxidative stress, and pulmonary artery pressure of chlorthalidone and hydrochlorothiazide as part of combined antihypertensive therapy in patients with arterial hypertension (AH) in combination with chronic obstructive pulmonary disease (COPD).Patients and Methods: the prospective study included 66 patients divided into two groups. As the main antihypertensive therapy, group 1 was prescribed with a combination of azilsartan medoxomil 40 mg and chlortalidone 12.5 mg as a fixed combination of Edarbi® CLO. Group 2 received a free combination of azilsartan medoxomil 40 mg (Edarbi®) and hydrochlorothiazide 12.5 mg. All patients underwent 24-hour blood pressure monitoring: (ABPM), echodopplercardiography, endothelium-dependent vasodilation, lipid peroxidation (LPO), nitric oxide metabolites, and endothelin-1 levels at baseline and after 6 months of treatment. Results: target blood pressure values (<130/80 mm Hg) were achieved in 91% of patients in group 1, and 51.5% in group 2 after 1 month of the study. After 6 months of treatment, all patients in both groups reached the target BP values, but in group 2, the dose of hydrochlorothiazide had to be increased to 25 mg. According to the ABPM data, after 6 months of treatment, group 1 showed a decrease in the morning surge in SBP by 7.0±2.1% and DBP by 10±7.3%. There was also an increase in the number of patients with the daily profile of «dipper» type to 78.8%. In group 2, there was a decrease in the morning surge in SBP by 6.3±5.9% and DBP by 4.8±4.6% after 6 months of treatment. There was an increase in the number of patients with the daily profile of «dipper» type to 36.4%. After 6 months of treatment, there was more pronounced improvement in laboratory parameters of group 1 characterizing endothelial dysfunction and oxidative stress. Statistically significant results were obtained for conjugated trienes, NO2, S, Imax, and endothelin-1 when comparing groups 1 and 2.Conclusion: treatment of AH in patients with concomitant COPD in the form of a fixed combination of azilsartan medoxomil and chlorthalidone versus free combination of azilsartan medoxomil with hydrochlorothiazide has a more pronounced antihypertensive effect, positively affecting the daily BP profile, pulmonary artery pressure, endothelial function and lipid peroxidation processes after 6 months of treatment.KEYWORDS: arterial hypertension, chronic obstructive pulmonary disease, endothelial dysfunction, lipid peroxidation, azilsartan medoxomil, chlorthalidone.FOR CITATION: Grigorieva N.Yu., Samolyuk M.O., Sheshina T.V. et al. How to improve the effectiveness of combination therapy of arterial hypertension in patients with concomitant chronic obstructive pulmonary disease? Russian Medical Inquiry. 2020;4(7):418–424. DOI: 10.32364/2587-6821-2020-4-7-418-424.

Sign in / Sign up

Export Citation Format

Share Document